• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pharmacol Sci . Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2

tetano

Editor, Senior Moderator
J Pharmacol Sci


. 2021 Sep;147(1):62-71.
doi: 10.1016/j.jphs.2021.05.004. Epub 2021 May 23.
Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2


Titilayo O Johnson[SUP] 1 [/SUP], Abayomi Emmanuel Adegboyega[SUP] 2 [/SUP], Opeyemi Iwaloye[SUP] 3 [/SUP], Omokehinde Abiodun Eseola[SUP] 4 [/SUP], Winfried Plass[SUP] 5 [/SUP], Boluwatife Afolabi[SUP] 6 [/SUP], Damilare Rotimi[SUP] 6 [/SUP], Eman I Ahmed[SUP] 7 [/SUP], Ashraf Albrakati[SUP] 8 [/SUP], Gaber E Batiha[SUP] 9 [/SUP], Oluyomi Stephen Adeyemi[SUP] 10 [/SUP]



Affiliations

Abstract

Owing to the urgent need for therapeutic interventions against the SARS-coronavirus 2 (SARS-CoV-2) pandemic, we employed an in silico approach to evaluate the SARS-CoV-2 inhibitory potential of newly synthesized imidazoles. The inhibitory potentials of the compounds against SARS-CoV-2 drug targets - main protease (Mpro), spike protein (Spro) and RNA-dependent RNA polymerase (RdRp) were investigated through molecular docking analysis. The binding free energy of the protein-ligand complexes were estimated, pharmacophore models were generated and the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of the compounds were determined. The compounds displayed various levels of binding affinities for the SARS-CoV-2 drug targets. Bisimidazole C2 scored highest against all the targets, with its aromatic rings including the two imidazole groups contributing to the binding. Among the phenyl-substituted 1H-imidazoles, C9 scored highest against all targets. C11 scored highest against Spro and C12 against Mpro and RdRp among the thiophene-imidazoles. The compounds interacted with HIS 41 - CYS 145 and GLU 288 - ASP 289 - GLU 290 of Mpro, ASN 501 of Spro receptor binding motif and some active site amino acids of RdRp. These novel imidazole compounds could be further developed as drug candidates against SARS-CoV-2 following lead optimization and experimental studies.

Keywords: Coronavirus; Drug discovery; Drug target; Molecular docking.
 
Back
Top Bottom